@ophthoscope.bsky.social
VIDEO: ‘Exciting’ uveitis pipeline includes oral, intravitreal and topical therapies
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS, provides an update on the progress of therapies for noninfectio
www.healio.com/news/ophthal...
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS, provides an update on the progress of therapies for noninfectio
www.healio.com/news/ophthal...
May 8, 2025 at 9:37 PM
VIDEO: ‘Exciting’ uveitis pipeline includes oral, intravitreal and topical therapies
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS, provides an update on the progress of therapies for noninfectio
www.healio.com/news/ophthal...
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS, provides an update on the progress of therapies for noninfectio
www.healio.com/news/ophthal...
Not Just Another Pilocarpine
An in-depth look at the new Qlosi™ topical drop for presbyopia.
crstoday.com/articles/apr...
An in-depth look at the new Qlosi™ topical drop for presbyopia.
crstoday.com/articles/apr...
May 8, 2025 at 8:51 PM
Not Just Another Pilocarpine
An in-depth look at the new Qlosi™ topical drop for presbyopia.
crstoday.com/articles/apr...
An in-depth look at the new Qlosi™ topical drop for presbyopia.
crstoday.com/articles/apr...
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/oral-ze...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/oral-ze...
May 8, 2025 at 6:40 PM
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/oral-ze...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/oral-ze...
Results of phase 2 clinical SAGA study of oral gildeuretinol for GA presented at ARVO 2025
Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.
www.ophthalmologytimes.com/view/results...
Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.
www.ophthalmologytimes.com/view/results...
May 8, 2025 at 5:09 PM
Results of phase 2 clinical SAGA study of oral gildeuretinol for GA presented at ARVO 2025
Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.
www.ophthalmologytimes.com/view/results...
Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.
www.ophthalmologytimes.com/view/results...
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME
Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to i
www.ophthalmologytimes.com/view/innoven...
Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to i
www.ophthalmologytimes.com/view/innoven...
May 8, 2025 at 5:09 PM
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME
Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to i
www.ophthalmologytimes.com/view/innoven...
Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to i
www.ophthalmologytimes.com/view/innoven...
Socioeconomic status linked with worse eye structure, function in glaucoma
SALT LAKE CITY — Lower socioeconomic status was linked with worse eye structure and function at initial presentation in patients undergoing selective laser trabeculoplasty, according to a pos
www.healio.com/news/ophthal...
SALT LAKE CITY — Lower socioeconomic status was linked with worse eye structure and function at initial presentation in patients undergoing selective laser trabeculoplasty, according to a pos
www.healio.com/news/ophthal...
May 8, 2025 at 5:07 PM
Socioeconomic status linked with worse eye structure, function in glaucoma
SALT LAKE CITY — Lower socioeconomic status was linked with worse eye structure and function at initial presentation in patients undergoing selective laser trabeculoplasty, according to a pos
www.healio.com/news/ophthal...
SALT LAKE CITY — Lower socioeconomic status was linked with worse eye structure and function at initial presentation in patients undergoing selective laser trabeculoplasty, according to a pos
www.healio.com/news/ophthal...
Topcon Healthcare acquires RetInSight to zero in on AI monitoring of OCT images
Topcon Healthcare acquired RetInSight, an Austria-based company that develops AI-driven software for eye care professionals, according to a Topcon press release. RetInSight’s AI algorith
www.healio.com/news/optomet...
Topcon Healthcare acquired RetInSight, an Austria-based company that develops AI-driven software for eye care professionals, according to a Topcon press release. RetInSight’s AI algorith
www.healio.com/news/optomet...
May 8, 2025 at 3:37 PM
Topcon Healthcare acquires RetInSight to zero in on AI monitoring of OCT images
Topcon Healthcare acquired RetInSight, an Austria-based company that develops AI-driven software for eye care professionals, according to a Topcon press release. RetInSight’s AI algorith
www.healio.com/news/optomet...
Topcon Healthcare acquired RetInSight, an Austria-based company that develops AI-driven software for eye care professionals, according to a Topcon press release. RetInSight’s AI algorith
www.healio.com/news/optomet...
Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP
Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.
www.ophthalmologytimes.com/view/beacon-...
Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.
www.ophthalmologytimes.com/view/beacon-...
May 8, 2025 at 2:33 PM
Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP
Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.
www.ophthalmologytimes.com/view/beacon-...
Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.
www.ophthalmologytimes.com/view/beacon-...
Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101
Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.
www.ophthalmologytimes.com/view/galimed...
Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.
www.ophthalmologytimes.com/view/galimed...
May 8, 2025 at 10:16 AM
Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101
Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.
www.ophthalmologytimes.com/view/galimed...
Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.
www.ophthalmologytimes.com/view/galimed...
Assessment of AI-enabled screening for ROP in low-resource settings
Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads
www.ophthalmologytimes.com/view/assessm...
Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads
www.ophthalmologytimes.com/view/assessm...
May 8, 2025 at 10:16 AM
Assessment of AI-enabled screening for ROP in low-resource settings
Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads
www.ophthalmologytimes.com/view/assessm...
Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads
www.ophthalmologytimes.com/view/assessm...
First patient dosed in VAN-2401 phase 1 clinical trial
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.
www.ophthalmologytimes.com/view/first-p...
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.
www.ophthalmologytimes.com/view/first-p...
May 8, 2025 at 10:15 AM
First patient dosed in VAN-2401 phase 1 clinical trial
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.
www.ophthalmologytimes.com/view/first-p...
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.
www.ophthalmologytimes.com/view/first-p...
Image Recognition Performance of GPT-4V(ision) and GPT-4o in Ophthalmology: Use of Images in Clinical Questions
Image Recognition Performance of GPT-4V(ision) and GPT-4o in Ophthalmology: Use of Images in Clinical Questions
www.dovepress.com/image-recogn...
Image Recognition Performance of GPT-4V(ision) and GPT-4o in Ophthalmology: Use of Images in Clinical Questions
www.dovepress.com/image-recogn...
May 8, 2025 at 7:26 AM
Image Recognition Performance of GPT-4V(ision) and GPT-4o in Ophthalmology: Use of Images in Clinical Questions
Image Recognition Performance of GPT-4V(ision) and GPT-4o in Ophthalmology: Use of Images in Clinical Questions
www.dovepress.com/image-recogn...
Image Recognition Performance of GPT-4V(ision) and GPT-4o in Ophthalmology: Use of Images in Clinical Questions
www.dovepress.com/image-recogn...
Demographic and Clinical Factors Associated with Mechanisms of Open Globe Injury in the United States: A Multi-Center Study
This study provides important insights into which demographic and clinical factors put patients at risk for different mechanisms of OGIs.
www.dovepress.com/demographic-...
This study provides important insights into which demographic and clinical factors put patients at risk for different mechanisms of OGIs.
www.dovepress.com/demographic-...
May 8, 2025 at 7:26 AM
Demographic and Clinical Factors Associated with Mechanisms of Open Globe Injury in the United States: A Multi-Center Study
This study provides important insights into which demographic and clinical factors put patients at risk for different mechanisms of OGIs.
www.dovepress.com/demographic-...
This study provides important insights into which demographic and clinical factors put patients at risk for different mechanisms of OGIs.
www.dovepress.com/demographic-...
ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience
www.ophthalmologytimes.com/view/ascrs-2...
Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience
www.ophthalmologytimes.com/view/ascrs-2...
May 8, 2025 at 4:10 AM
ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience
www.ophthalmologytimes.com/view/ascrs-2...
Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience
www.ophthalmologytimes.com/view/ascrs-2...
Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
Eye, Published online: 07 May 2025; doi:10.1038/s41433-025-03838-7Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
www.nature.com/articles/s41...
Eye, Published online: 07 May 2025; doi:10.1038/s41433-025-03838-7Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
www.nature.com/articles/s41...
May 8, 2025 at 3:53 AM
Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
Eye, Published online: 07 May 2025; doi:10.1038/s41433-025-03838-7Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
www.nature.com/articles/s41...
Eye, Published online: 07 May 2025; doi:10.1038/s41433-025-03838-7Association between leukocyte telomere length and incident glaucoma: A prospective UK biobank study
www.nature.com/articles/s41...
ARVO 2025: Barsha Lal, PhD, presents an atropine study that addresses families' accomodative concerns
A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.
www.ophthalmologytimes.com/view/arvo-20...
A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.
www.ophthalmologytimes.com/view/arvo-20...
May 7, 2025 at 10:20 PM
ARVO 2025: Barsha Lal, PhD, presents an atropine study that addresses families' accomodative concerns
A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.
www.ophthalmologytimes.com/view/arvo-20...
A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.
www.ophthalmologytimes.com/view/arvo-20...
Phase 2 data on IBI302 announced by Innovent Biologics
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/phase-2...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/phase-2...
May 7, 2025 at 8:01 PM
Phase 2 data on IBI302 announced by Innovent Biologics
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/phase-2...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
www.ophthalmologytimes.com/view/phase-2...
FDA grants RMAT designation to gene therapy for Leber congenital amaurosis
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to OPGx-LCA5 for the treatment of Leber
www.healio.com/news/ophthal...
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to OPGx-LCA5 for the treatment of Leber
www.healio.com/news/ophthal...
May 7, 2025 at 7:49 PM
FDA grants RMAT designation to gene therapy for Leber congenital amaurosis
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to OPGx-LCA5 for the treatment of Leber
www.healio.com/news/ophthal...
Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to OPGx-LCA5 for the treatment of Leber
www.healio.com/news/ophthal...
Topcon announces launch of IDHea
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.
www.ophthalmologytimes.com/view/topcon-...
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.
www.ophthalmologytimes.com/view/topcon-...
May 7, 2025 at 6:30 PM
Topcon announces launch of IDHea
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.
www.ophthalmologytimes.com/view/topcon-...
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.
www.ophthalmologytimes.com/view/topcon-...
CDC terminates infection control advisory committee
The CDC has terminated an advisory committee responsible for issuing federal guidance on the prevention and control of health care-associated infections and the spread of antimicrobial resistance, HHS confirmed to
www.healio.com/news/infecti...
The CDC has terminated an advisory committee responsible for issuing federal guidance on the prevention and control of health care-associated infections and the spread of antimicrobial resistance, HHS confirmed to
www.healio.com/news/infecti...
May 7, 2025 at 6:18 PM
CDC terminates infection control advisory committee
The CDC has terminated an advisory committee responsible for issuing federal guidance on the prevention and control of health care-associated infections and the spread of antimicrobial resistance, HHS confirmed to
www.healio.com/news/infecti...
The CDC has terminated an advisory committee responsible for issuing federal guidance on the prevention and control of health care-associated infections and the spread of antimicrobial resistance, HHS confirmed to
www.healio.com/news/infecti...
Phase 2 BETTER trial results shared at ARVO 2025
Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.
www.ophthalmologytimes.com/view/phase-2...
Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.
www.ophthalmologytimes.com/view/phase-2...
May 7, 2025 at 6:13 PM
Phase 2 BETTER trial results shared at ARVO 2025
Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.
www.ophthalmologytimes.com/view/phase-2...
Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.
www.ophthalmologytimes.com/view/phase-2...
